A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI

PHASE2CompletedINTERVENTIONAL
Enrollment

652

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Percutaneous Coronary Intervention
Interventions
DRUG

clopidogrel

Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg

DRUG

PRT060128

80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg

Trial Locations (59)

Unknown

Portola Investigational Site, La Jolla

Portola Investigational Site, Torrance

Portola Investigational Site, Washington D.C.

Portola Investigational Site, Jacksonville

Portola Investigational Site, Tallahassee

Portola Investigational Site, Augusta

Portola Investigational Site, Lexington

Portola Investigational Site, New Orleans

Portola Investigational Site, Portland

Portola Investigational Site, Baltimore

Portola Investigational Site, Detroit

Portola Investigational Site, Grand Blanc

Portola Investigational Site, Brooklyn

Portola Investigational Site, Charleston

Portola Investigational Site, Winston-Salem

Portola Investigational Site, Cincinnati

Portola Investigational Site, Hershey

Portola Investigational Site, Lancaster

Portola Investigational Site, Seattle

Portola Investigational Site, Graz

Portola Investigational Site, Vienna

Portola Investigational Site, Calgary

Portola Investigational Site, Edmonton

Portola Investigational Site, Vancouver

Portola Investigational Site, St. John's

Portola Investigational Site, Newmarket

Portola Investigational Site, Toronto

Portola Investigational Site, Bad Oeynhausen

Portola Investigational Site, Bad Rothenfelde

Portola Investigational Site, Berlin

Portola Investigational Site, Bernau

Portola Investigational Site, Dachau

Portola Investigational Site, Dortmund

Portola Investigational Site, Dresden

Portola Investigational Site, Göttingen

Portola Investigational Site, Halle

Portola Investigational Site, Hanover

Portola Investigational Site, Heidelberg

Portola Investigational Site, Kassel

Portola Investigational Site, Kiel

Portola Investigational Site, Langen

Portola Investigational Site, Ludwigshafen

Portola Investigational Site, Lübeck

Portola Investigational Site, Mainz

Portola Investigational Site, Mönchengladbach

Portola Investigational Site, Munich

Portola Investigational Site, Neuss

Portola Investigational Site, Rostock

Portola Investigational Site, Schwalmstadt

Portola Investigational Site, Traunstein

Portola Investigational Site, Trier

Portola Investigational Site, Witten

Portola Investigational Site, Wuppertal

Portola Investigational Site, Bydgoszcz

Portola Investigational Site, Gdansk

Portola Investigational Site, Lodz

Portola Investigational Site, Lublin

Portola Investigational Site, Szczecin

Portola Investigational Site, Warsaw

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY

NCT00751231 - A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI | Biotech Hunter | Biotech Hunter